Acer Therapeutics cuts 60% of staff

Acer Therapeutics, a rare-disease drugmaker, has cut 60 percent of its workforce two weeks after the FDA refused to approve its lead drug candidate Edsivo for a rare connective tissue disorder.

Advertisement

The layoffs, part of a restructuring effort that also includes halting pre-commercial activities for Edsivo, are expected to help Acer continue to operate through 2020. 

The head count was reduced from 48 employees to 19 employees. 

“The company estimates that it will record a one-time severance-related charge of approximately $1.5 million associated with the workforce reduction in the second quarter of 2019,” Acer said in a Securities and Exchange Commission filing.

More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.